For healthcare professionals only

Research Article

Prostacyclin and thromboxane A2 in thrombotic thrombocytopenic purpura.

Br Med J (Clin Res Ed) 1981; 283 doi: (Published 21 November 1981) Cite this as: Br Med J (Clin Res Ed) 1981;283:1351
  1. S H Lee,
  2. J S Wainscoat,
  3. H Zeitlin,
  4. F G Bolton,
  5. H A Leaver,
  6. A Seawright,
  7. J M Preece


    A study was conducted to find whether a deficiency in prostacyclin (prostaglandin I2; PGI2) is implicated in the pathogenesis of thrombotic thrombocytopenic purpura. Plasma samples from two patients with the disease before treatment and from 22 healthy controls were therefore assayed for concentrations of 6-oxo-PGF1 alpha and thromboxane B2, the stable metabolites of PGI2 and thromboxane A2, respectively. Neither of the patients responded to treatment, which in one case included an infusion of PGI2. Both patients had normal concentrations of 6-oxo-PGF1 alpha and thromboxane B2, thus implying that circulating amounts of PGI2 and thromboxane A2 were also normal. These findings suggest that 6-oxo-PGF1 alpha may be detectable in normal amounts in thrombotic thrombocytopenic purpura and that the condition need not be associated with a high concentration of thromboxane A2.